Table 3.
Adjusted hazard ratio and incidence of meningioma by duration of tamoxifen therapy in patients with breast cancer with and without tamoxifen use.
| Tamoxifen exposed | n | Event | Person-years | IR | Adjusted HR‡
(95% CI) |
Adjusted HR‡
(95% CI) |
|---|---|---|---|---|---|---|
| Without using tamoxifen | 30,929 | 35 | 116,553 | 3.00 | 1.00 | |
| Duration on tamoxifen | ||||||
| ≤365 days | 17,692 | 11 | 51,514 | 2.14 | 0.69 (0.34, 1.38) | 1.00 |
| 366–1,500 days | 23,341 | 23 | 113,787 | 2.02 | 0.77 (0.44, 1.32) | 1.00 (0.48, 2.07) |
| >1,500 days | 9,409 | 8 | 72,271 | 1.11 | 0.42 (0.19, 0.91)* | 0.51 (0.20, 1.31) |
CI, confidence interval; HR, hazard ratio; IR, incidence density rates (per 10,000 person-years). ‡Adjusted for age, comorbidity, steroid use, statin use, and thiazide diuretics use, treatment I, and treatment II. *P < 0.05.